These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30908653)

  • 1. Sclerotherapy and Topical Nasal Propranolol: An Effective and Safe Therapy for HHT-Epistaxis.
    Esteban-Casado S; Martín de Rosales Cabrera AM; Usarralde Pérez A; Martínez Simón JJ; Zhan Zhou E; Marcos Salazar MS; Pérez Encinas M; Botella Cubells L
    Laryngoscope; 2019 Oct; 129(10):2216-2223. PubMed ID: 30908653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report.
    Mei-Zahav M; Blau H; Bruckheimer E; Zur E; Goldschmidt N
    J Otolaryngol Head Neck Surg; 2017 Oct; 46(1):58. PubMed ID: 28978360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sclerotherapy on Demand with Polidocanol to Treat HHT Nosebleeds.
    Marcos S; Botella LM; Albiñana V; Arbia A; de Rosales AM
    J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sclerotherapy for Hereditary Hemorrhagic Telangiectasia-Related Epistaxis: A Systematic Review.
    Thiele B; Abdel-Aty Y; Marks L; Lal D; Marino M
    Ann Otol Rhinol Laryngol; 2023 Jan; 132(1):82-90. PubMed ID: 35152768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Timolol in a Novel Intranasal Thermosensitive Gel for Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis: A Randomized Clinical Trial.
    Peterson AM; Lee JJ; Kallogjeri D; Schneider JS; Chakinala MM; Piccirillo JF
    JAMA Otolaryngol Head Neck Surg; 2020 Nov; 146(11):1006-1014. PubMed ID: 32940653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
    Whitehead KJ; Sautter NB; McWilliams JP; Chakinala MM; Merlo CA; Johnson MH; James M; Everett EM; Clancy MS; Faughnan ME; Oh SP; Olitsky SE; Pyeritz RE; Gossage JR
    JAMA; 2016 Sep; 316(9):943-51. PubMed ID: 27599329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective randomized trial of sclerotherapy vs standard treatment for epistaxis due to hereditary hemorrhagic telangiectasia.
    Boyer H; Fernandes P; Le C; Yueh B
    Int Forum Allergy Rhinol; 2015 May; 5(5):435-40. PubMed ID: 25643928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Office-based sclerotherapy for recurrent epistaxis due to hereditary hemorrhagic telangiectasia: a pilot study.
    Boyer H; Fernandes P; Duran O; Hunter D; Goding G
    Int Forum Allergy Rhinol; 2011; 1(4):319-23. PubMed ID: 22287439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a topical sesame/rose geranium oil compound in patients with hereditary hemorrhagic telangiectasia associated epistaxis.
    Reh DD; Hur K; Merlo CA
    Laryngoscope; 2013 Apr; 123(4):820-2. PubMed ID: 23401038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Injection of bevacizumab and cyanoacrylate glue for hereditary hemorrhagic telangiectasia.
    Khoueir N; Borsik M; Camous D; Herman P; Verillaud B
    Laryngoscope; 2019 Oct; 129(10):2210-2215. PubMed ID: 31566760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complications from office sclerotherapy for epistaxis due to hereditary hemorrhagic telangiectasia (HHT or Osler-Weber-Rendu).
    Hanks JE; Hunter D; Goding GS; Boyer HC
    Int Forum Allergy Rhinol; 2014 May; 4(5):422-7. PubMed ID: 24431220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sclerotherapy Versus Cautery/Laser Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia.
    Woodard TD; Yappel-Sinkko KB; Wang X; McCrae KR; Parambil JG
    Laryngoscope; 2022 May; 132(5):920-925. PubMed ID: 34160081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal topical estrogen in the management of epistaxis in hereditary hemorrhagic telangiectasia.
    Minami K; Haji T
    Acta Otolaryngol; 2016; 136(5):528-31. PubMed ID: 26808464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective pilot study of Floseal® for the treatment of anterior epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT).
    Lee JM; Wu V; Faughnan ME; Lasso A; Figol A; Kilty SJ
    J Otolaryngol Head Neck Surg; 2019 Oct; 48(1):48. PubMed ID: 31615556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia.
    Yin LX; Reh DD; Hoag JB; Mitchell SE; Mathai SC; Robinson GM; Merlo CA
    Laryngoscope; 2016 May; 126(5):1029-32. PubMed ID: 26393959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT).
    Wirsching KEC; Haubner F; Kühnel TS
    Eur Arch Otorhinolaryngol; 2017 Apr; 274(4):1891-1896. PubMed ID: 28070641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical Propranolol Improves Epistaxis Control in Hereditary Hemorrhagic Telangiectasia (HHT): A Randomized Double-Blind Placebo-Controlled Trial.
    Mei-Zahav M; Gendler Y; Bruckheimer E; Prais D; Birk E; Watad M; Goldschmidt N; Soudry E
    J Clin Med; 2020 Sep; 9(10):. PubMed ID: 32998220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
    Dupuis-Girod S; Ambrun A; Decullier E; Samson G; Roux A; Fargeton AE; Rioufol C; Schwiertz V; Disant F; Chapuis F; Donazzolo Y; Paintaud G; Edery P; Faure F
    MAbs; 2014; 6(3):794-9. PubMed ID: 24481211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT).
    Zarrabeitia R; Fariñas-Álvarez C; Santibáñez M; Señaris B; Fontalba A; Botella LM; Parra JA
    Health Qual Life Outcomes; 2017 Jan; 15(1):19. PubMed ID: 28114930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose.
    Dheyauldeen S; Østertun Geirdal A; Osnes T; Vartdal LS; Dollner R
    Laryngoscope; 2012 Jun; 122(6):1210-4. PubMed ID: 22565282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.